No products in the cart.
The brain can change throughout life. It can strengthen existing connections, form new ones, and adapt after learning or injury. This ability is known as neuroplasticity.
Because neuroplasticity plays an important role in learning, memory, and recovery, researchers are studying whether certain peptides can influence the biological pathways involved in it.
Some early findings are interesting. However, there is an important distinction between showing an effect in cells or animals and proving a meaningful benefit in humans. For most peptides discussed in this area, human evidence remains limited.
Here is what current research actually shows.
What Is Neuroplasticity?
Neuroplasticity is the brain’s ability to change its connections and function in response to experiences, learning, and injury.
One part of this process involves strengthening or weakening connections between neurons. Another involves changes in the structure of neurons and the formation of new connections.
These processes are influenced by several signaling molecules, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). BDNF, in particular, plays an important role in synaptic plasticity, learning, memory, and neuronal survival. That is one reason BDNF has become an important target in research into brain function and neuroplasticity.
Why Are Researchers Interested in BDNF and NGF?
BDNF helps neurons respond to activity and supports changes at synapses, the points where neurons communicate with each other.
It works partly through the TrkB receptor and activates signaling pathways involved in synaptic function and plasticity. Research in both animals and humans has linked BDNF signaling with learning and memory processes.
NGF is another neurotrophic factor involved in neuronal survival and function.
Because these pathways are important to normal brain function, researchers have investigated whether compounds that influence them could potentially support neurological recovery or cognitive processes.
However, increasing a growth factor does not automatically mean that a person will experience better memory or cognition. That connection still needs to be demonstrated in properly designed human trials.
How Could Peptides Affect Neuroplasticity?
Different peptides are being studied through different mechanisms. Some experimental compounds appear to influence neurotrophic factors, while others affect signaling pathways involved in synaptic function or neuronal growth.
Three areas are particularly relevant.
BDNF and NGF Signaling
Some peptides have been shown to change BDNF or NGF expression in animal or laboratory studies.
For example, Semax has increased BDNF and NGF-related activity in several experimental studies. Noopept has also been shown to increase BDNF and NGF messenger RNA in the hippocampus of rats.
These findings provide a possible biological explanation for some of the effects being investigated.
They do not, however, prove that these compounds improve cognition in healthy humans.
Synaptic Growth and Connectivity
Neuroplasticity is not only about growth factors. It also involves changes in synapses and neuronal structure.
Researchers therefore study compounds that may influence processes such as synaptogenesis, dendritic growth, and long-term potentiation.
These effects are often measured in cell cultures or animal models, which means they still need to be translated into meaningful human outcomes.
Neuroprotection and Recovery
Some peptides are also being studied for their potential effects on neuronal survival, inflammation, or recovery after neurological injury.
This is particularly relevant to research involving stroke and other forms of brain injury. However, positive results in an injury model do not necessarily mean that the same compound will improve cognition in a healthy person.
Which Peptides Are Being Studied for Neuroplasticity?
Several compounds have attracted attention in this area. Their evidence levels are not the same.
Semax and Neuroplasticity
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH).
It has been studied extensively in Russian research, including research involving neurological conditions such as ischemic stroke.
Animal studies provide some of the clearest evidence for its effects on neurotrophic pathways. In rats, intranasal Semax increased BDNF levels in the basal forebrain and changed BDNF and NGF gene expression in the hippocampus and other brain regions.
Human clinical research has also investigated Semax in stroke patients. For example, one clinical study examined 110 patients during stroke rehabilitation and reported changes in plasma BDNF levels and functional outcomes among patients receiving Semax.
However, these studies were conducted in people with neurological disease rather than healthy adults taking Semax specifically to improve cognition.
So while Semax has a longer clinical research history than many experimental peptides, its ability to enhance neuroplasticity or cognitive performance in healthy people remains unproven.
Selank and Neuroplasticity
Selank is a synthetic peptide related to the naturally occurring peptide tuftsin.
It has mainly attracted research interest for its potential effects on anxiety, stress responses, and cognitive function.
Preclinical research has found effects on BDNF-related signaling in brain tissue, providing a possible connection with neuroplasticity. Human research has also investigated Selank in anxiety-related conditions.
However, the available evidence does not establish that Selank increases neuroplasticity enough to improve memory or learning in healthy adults.
More controlled and independently replicated human research would be needed to answer that question.
Noopept and Neuroplasticity
Noopept, also known as omberacetam, is a synthetic dipeptide-like nootropic compound that has been investigated primarily in Russian research.
One animal study found that noopept increased the expression of BDNF and NGF in the hippocampus of rats. The researchers suggested that these changes could contribute to its reported neurotrophic effects.
Noopept has also been studied clinically, but the evidence base is limited compared with the large randomized trials normally used to establish the effectiveness of a cognitive-enhancing treatment.
The BDNF and NGF findings are therefore best described as preclinical evidence, rather than proof that Noopept improves neuroplasticity in humans.
Dihexa and Neuroplasticity
Dihexa attracted attention because early research suggested that it could influence the HGF/c-Met signaling pathway, which is involved in cellular growth and signaling.
Early experimental work generated claims about unusually strong effects on synaptic formation. Those claims now need to be treated with substantial caution.
In 2025, several papers from the research program associated with Dihexa were retracted following concerns about data integrity. A paper directly related to the HGF/c-Met mechanism was among the retracted work.
That does not mean every biological question surrounding the pathway has been disproven. It does mean that the original evidence supporting some of the strongest Dihexa claims can no longer be treated as reliable.
Dihexa therefore remains an experimental compound without established clinical evidence showing that it improves cognition or neuroplasticity in humans.
PE-22-28 and Neuroplasticity
PE-22-28 is an experimental peptide derived from the larger peptide known as spadin.
It has been investigated because of its interaction with TREK-1, a potassium channel involved in neuronal activity.
In animal and laboratory studies, PE-22-28 has shown effects related to neurogenesis and synaptogenesis. One study reported increased neurogenesis after four days of treatment in mice and increased PSD-95, a protein associated with synaptic function, in cultured neurons.
These findings make PE-22-28 interesting for further research.
But they remain preclinical findings. There is not enough human evidence to determine whether the compound produces meaningful improvements in memory, learning, or other aspects of cognition.
How Strong Is the Evidence for Peptides and Neuroplasticity?
The evidence varies considerably between compounds.
| Peptide | Main area studied | Evidence relevant to neuroplasticity | Human evidence |
| Semax | BDNF, NGF, neuroprotection | Animal and clinical research | Limited |
| Selank | Anxiety, stress, BDNF-related pathways | Animal and some human research | Limited |
| Noopept | BDNF, NGF, cognition | Mainly preclinical for these mechanisms | Limited |
| Dihexa | HGF/c-Met, synaptic growth | Early preclinical research with major reliability concerns | No established evidence |
| PE-22-28 | TREK-1, neurogenesis, synaptogenesis | Preclinical | No established evidence |
The important point is that “studied in humans” does not mean “proven to enhance neuroplasticity in humans.”
For example, Semax has been investigated clinically in stroke patients. That is different from demonstrating that Semax improves learning or memory in healthy adults.
Likewise, showing increased BDNF in an animal model does not establish that the same effect occurs in the human brain or that it produces a noticeable cognitive benefit.
Do Peptides Actually Improve Cognition in Healthy People?
This remains one of the biggest unanswered questions.
Much of the research into peptide-related neuroplasticity has focused on animals, cell cultures, or people with neurological conditions.
That creates several challenges.
A compound can produce a promising biological effect in a rat brain without producing the same effect in humans. Differences in metabolism, dose, brain exposure, receptor activity, and disease biology can all affect the outcome.
Researchers studying BDNF-based approaches have repeatedly highlighted the difficulty of translating promising preclinical findings into successful clinical treatments.
So far, the evidence is not strong enough to conclude that these experimental peptides reliably improve cognition in healthy adults.
Why Animal Studies Are Not Enough
Animal studies are an important part of drug research. They help scientists understand possible mechanisms and identify compounds worth investigating further.
But they are an early step, not the final answer.
A peptide that changes BDNF expression in a rat brain may not produce the same change in a human brain.
Researchers also need to determine:
- whether enough of the compound reaches the brain
- how long it remains active
- which receptors and pathways it affects
- whether the effects are dose dependent
- whether the effects remain after treatment stops
- whether long-term use creates unwanted effects
This is especially important for experimental compounds that have never undergone large human trials.
Are Peptides for Neuroplasticity Safe?
Safety is another major unanswered question.
Some peptides have a longer history of clinical investigation than others. Semax and Selank, for example, have been studied in human populations, particularly in Russian clinical research.
Other compounds discussed here have little or no human safety data.
Long-term effects are particularly difficult to determine when there are few controlled human studies.
There is also a broader scientific question. Neuroplasticity is a tightly regulated biological process. Increasing activity in a pathway involved in growth or synaptic signaling is not automatically beneficial in every situation.
For experimental peptides, safety therefore needs to be evaluated compound by compound, rather than assuming that all peptides with a similar proposed mechanism have similar safety profiles.
Conclusion
Peptides and neuroplasticity are connected through real biological pathways, including BDNF, NGF, synaptic signaling, and neuronal growth.
But promising biology is not the same as proven clinical benefit.
Semax and Selank have more human research history than newer experimental compounds, while Noopept, Dihexa, and PE-22-28 have important gaps in the evidence. Dihexa requires particular caution because several papers supporting its early research program were retracted.
For now, the strongest conclusion is that peptide research offers interesting clues about neuroplasticity, but much more human research is needed before these compounds can be considered established tools for improving cognition or brain plasticity.
